AU2020228367A1 - Antigen binding proteins that bind BCMA - Google Patents

Antigen binding proteins that bind BCMA Download PDF

Info

Publication number
AU2020228367A1
AU2020228367A1 AU2020228367A AU2020228367A AU2020228367A1 AU 2020228367 A1 AU2020228367 A1 AU 2020228367A1 AU 2020228367 A AU2020228367 A AU 2020228367A AU 2020228367 A AU2020228367 A AU 2020228367A AU 2020228367 A1 AU2020228367 A1 AU 2020228367A1
Authority
AU
Australia
Prior art keywords
seq
amino acid
acid sequence
light chain
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020228367A
Other languages
English (en)
Inventor
Xia Cao
Heyue Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vivasor Inc
Original Assignee
Vivasor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vivasor Inc filed Critical Vivasor Inc
Publication of AU2020228367A1 publication Critical patent/AU2020228367A1/en
Assigned to VIVASOR, INC. reassignment VIVASOR, INC. Request for Assignment Assignors: SORRENTO THERAPEUTICS, INC.
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2020228367A 2019-02-26 2020-02-25 Antigen binding proteins that bind BCMA Abandoned AU2020228367A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962810771P 2019-02-26 2019-02-26
US62/810,771 2019-02-26
US201962811431P 2019-02-27 2019-02-27
US62/811,431 2019-02-27
PCT/US2020/019763 WO2020176549A1 (en) 2019-02-26 2020-02-25 Antigen binding proteins that bind bcma

Publications (1)

Publication Number Publication Date
AU2020228367A1 true AU2020228367A1 (en) 2021-10-14

Family

ID=72238662

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020228367A Abandoned AU2020228367A1 (en) 2019-02-26 2020-02-25 Antigen binding proteins that bind BCMA

Country Status (12)

Country Link
US (1) US12630642B2 (cg-RX-API-DMAC7.html)
EP (1) EP3930852A4 (cg-RX-API-DMAC7.html)
JP (1) JP7554759B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210133261A (cg-RX-API-DMAC7.html)
CN (1) CN113874082B (cg-RX-API-DMAC7.html)
AU (1) AU2020228367A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021016791A2 (cg-RX-API-DMAC7.html)
CA (1) CA3130765A1 (cg-RX-API-DMAC7.html)
IL (1) IL285813A (cg-RX-API-DMAC7.html)
MX (1) MX2021010281A (cg-RX-API-DMAC7.html)
SG (1) SG11202109163YA (cg-RX-API-DMAC7.html)
WO (1) WO2020176549A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114650829A (zh) * 2019-09-05 2022-06-21 索伦托药业有限公司 结合bcma的二聚体抗原受体(dar)
TWI917473B (zh) 2020-11-02 2026-03-11 新加坡商蜂鳥生物科技私人有限公司 Bcma/taci抗原結合分子
KR20250152662A (ko) 2020-12-31 2025-10-23 사노피 NKp46 및 CD123에 결합하는 다기능성 자연살해(NK) 세포 관여자
WO2022184082A1 (en) 2021-03-03 2022-09-09 Sorrento Therapeutics, Inc. Antibody-drug conjugates comprising an anti-bcma antibody
WO2023227790A1 (en) 2022-05-27 2023-11-30 Sanofi Natural killer (nk) cell engagers binding to nkp46 and bcma variants with fc-engineering
WO2023237366A1 (en) * 2022-05-27 2023-12-14 Sanofi Anti-bcma antibodies
CN119841951B (zh) * 2024-12-25 2025-10-14 厦门大学附属第一医院(厦门市第一医院、厦门市红十字会医院、厦门市糖尿病研究所) 一种抗bcma抗体或其抗原结合片段及其制备方法和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6342220B1 (en) * 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
GB9908533D0 (en) * 1999-04-14 1999-06-09 Novartis Ag Organic compounds
US7214786B2 (en) * 2000-12-14 2007-05-08 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
CN1838968A (zh) * 2003-08-08 2006-09-27 艾伯吉尼斯公司 针对甲状旁腺激素(pth)之抗体和其用途
JP5718640B2 (ja) * 2007-08-21 2015-05-13 アムジエン・インコーポレーテツド ヒトc−fms抗原結合性タンパク質
MX2015005546A (es) * 2012-11-13 2015-08-05 Regeneron Pharma Anticuerpos anti-receptor de procineticinas (prokr) y usos de los mismos.
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Bcma抗原結合蛋白質
TW201632559A (zh) * 2015-02-22 2016-09-16 索倫多醫療公司 結合cd137之抗體治療劑
HUE057285T2 (hu) 2015-04-13 2022-04-28 Pfizer Terápiás ellenanyagok és alkalmazásaik
TWI811023B (zh) * 2015-08-17 2023-08-01 美商健生生物科技公司 抗bcma抗體,結合bcma及cd3之雙特異性抗原結合分子及其用途
MA44254A (fr) * 2016-02-17 2018-12-26 Seattle Genetics Inc Anticorps bcma et leur utilisation pour traiter le cancer et les troubles immunologiques
UA126813C2 (uk) * 2017-08-01 2023-02-08 Медімм'Юн, Ллк Моноклональний кон’югат антитіло-лікарський засіб до bcma
US20200224160A1 (en) * 2018-02-27 2020-07-16 Sorrento Therapeutics, Inc. Process for dna integration using rna-guided endonucleases
CN109265550B (zh) * 2018-09-25 2020-09-15 华东师范大学 Bcma抗体、嵌合抗原受体和药物
CN114650829A (zh) * 2019-09-05 2022-06-21 索伦托药业有限公司 结合bcma的二聚体抗原受体(dar)

Also Published As

Publication number Publication date
EP3930852A1 (en) 2022-01-05
WO2020176549A1 (en) 2020-09-03
CA3130765A1 (en) 2020-09-03
KR20210133261A (ko) 2021-11-05
US20210388097A1 (en) 2021-12-16
US12630642B2 (en) 2026-05-19
SG11202109163YA (en) 2021-09-29
EP3930852A4 (en) 2022-12-28
CN113874082B (zh) 2024-12-06
JP7554759B2 (ja) 2024-09-20
IL285813A (en) 2021-10-31
JP2022521956A (ja) 2022-04-13
BR112021016791A2 (pt) 2021-11-16
CN113874082A (zh) 2021-12-31
MX2021010281A (es) 2021-09-23

Similar Documents

Publication Publication Date Title
US12630642B2 (en) Antigen binding proteins that bind BCMA
US20250084163A1 (en) Antigen Binding Proteins That Bind ROR1
CN107849136B (zh) 抗TfR抗体及其在治疗增殖性和炎性疾病中的用途
US20220144966A1 (en) Engineered Variant Antibodies that Bind CD38
JP2024036508A (ja) Cd38に結合するバリアント抗体
US20230235059A1 (en) Anti-pd1 antibodies and uses thereof
US12624103B2 (en) Engineered antibodies that bind LAG3
HK40064182A (en) Antigen binding proteins that bind bcma

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: VIVASOR, INC.

Free format text: FORMER APPLICANT(S): SORRENTO THERAPEUTICS, INC.

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application